revenue
51–53 $million
FY 2026
official guidance
IRIDEX CORPORATION
Last · NASDAQ$0.929+0.039 (+4.38%)stale · yahoo · 56h ago
Market cap$16.32M17.6M sh
P/E · TTM-4.6fwd — · eps -0.20 · loss
Beta0.67vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.61$1.65
Volume292.5Ksession
| Revenue | $24.4M |
|---|---|
| Operating income | $-1.4M |
| Net income | $-1.8M |
| Free cash flow | $-1.3M |
| Operating margin | -5.6% |
| Net margin | -7.3% |
| Return on equity | -49.2% |
| Period | 2026 |
Loading chart…
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strong BuyBuyHoldSellStrong Sell
cautious hold/avoid buying aggressively after the call.
IRIDEX delivered strong Cyclo G6 probe growth—17,700 units, up 35%, and $3.9 million of G6 revenue, up 19%—but total revenue fell 7% to $12.6 million, retina revenue dropped to $6.5 million from $8.0 million, and adjusted EBITDA was negative $0.4 million. The bull case is improving glaucoma utilization and future margin gains from outsourcing; the key tension is that the $51–$53 million FY2026 revenue target requires a much stronger second half despite distributor timing, regulatory delays, competitive console pressure, and only $4.7 million of cash.
Near term
The second-half revenue recovery is the immediate test: management expects low-single-digit retina growth and low-double-digit glaucoma growth, with Q4 historically the strongest quarter.
Cyclo G6 probe demand remains the clearest positive indicator, but management acknowledged Japan and Europe placed heavier orders ahead of blackout periods; the next quarter could show a corresponding inventory-driven decline.
Cyclo G6 system placements fell to 18 from 35 year over year. A rebound in Europe, the Middle East and Africa and stronger Q4 capital-equipment sales are necessary to support the outlook.
Cash generation may be pressured in Q3 by safety-stock purchases. Although management reported positive operating cash flow, cash increased only $0.1 million to $4.7 million.
The company reaffirmed FY2026 revenue guidance of $51 million–$53 million, excluding the Middle East, and adjusted operating expenses of $19 million–$19.5 million.
Longer term
The glaucoma model is becoming more utilization-led: higher probe volumes, increased ASPs, reimbursement support from Medicare LCDs, and targeted selling through MedScout could create better recurring revenue than relying on console placements.
The planned headquarters relocation and multiyear migration to lower-cost contract manufacturers could improve gross margins in 2027, but execution depends on maintaining regulatory registrations and supply continuity during the transition.
The retina recovery depends materially on international regulatory and reimbursement progress, including expected European MDR approval for PASCAL in the first half of 2027 and the UK MicroPulse registry.
Competitive pressure remains a structural concern in new Cyclo G6 console placements, particularly in Germany and Austria. The call provided evidence of probe adoption but not proof that the company is winning enough new platforms to expand the installed base at an attractive rate.
Red flags
The quarter's revenue decline was concentrated in retina, yet management characterized the issues as temporary without quantifying how much of the $1.5 million year-over-year retina shortfall will recover or when China and other regulatory constraints will normalize.
Meeting the unchanged $51 million–$53 million outlook requires a substantial second-half acceleration after first-half weakness, while management simultaneously warned of continued regional ordering choppiness and a likely next-quarter decline in markets that stocked up.
The cash position remains thin at $4.7 million. Safety-stock investment, relocation costs, regulatory blackout periods, and inventory normalization could leave limited room for further execution setbacks.
System sales declined nearly by half year over year, and management attributed the weakness partly to persistent competition rather than only timing. The Q&A did not establish that the competitive issue is temporary.
Adjusted EBITDA deteriorated from positive $21,000 to a loss of $400,000 despite lower operating expenses, so the claimed financial inflection has not yet translated into sustainable earnings improvement.
Forward outlook
revenue growth
1–5 pct
FY 2026
official guidance
revenue growth
—
FY 2026
management framework
revenue growth
—
FY 2026
management framework
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.04
Est. revenue
12.6M
Earnings transcripts
Press & signals
- GlobeNewswire
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
- GlobeNewswire
Iridex Reports Second Quarter 2026 Financial Results
- GlobeNewswire
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering